Resveratrol is a bioactive compound in many foods. Since its anticancer activity was reported in 1997, its health benefits have been intensively investigated. Resveratrol has antioxidant, anti-inflammatory, immunomodulatory, glucose and lipid regulatory, neuroprotective, and cardiovascular protective effects, therefore, can protect against diverse chronic diseases, such as cardiovascular diseases (CVDs), cancer, liver diseases, obesity, diabetes, Alzheimer's disease, and Parkinson's disease. This review summarizes the main findings of resveratrol-related health benefits in recent epidemiological surveys, experimental studies, and clinical trials, highlighting its related molecular mechanisms. Resveratrol, therefore, has been regarded as a potent candidate for the development of nutraceuticals and pharmaceuticals to prevent and treat certain chronic diseases. Foods 2020, 9, 340 Iranian (Tehranian)/Iran Cross-sectional study, part of the TLG study N = 2618 (male, 1162; female, 1456) Quartiles: Q1: 0.014 mg/day Q2: 0.015-0.027 mg/day Q3: 0.028-0.053 mg/day Q4: 0.054 mg/day (FFQ on a daily frequency, 1 year prior) Null: Significantly associated with WC, TG, HDL, BG, and MS Unfavorable: The top quantile of intake (0.054 mg/day and more) was positively associated with high BP (HR = 1.52; 95% CI: 1.02-2.27) [19] Spanish/Spain Cross-sectional study, part of the PREDIMED study N = 1000 (male, 479; female, 521) Quintiles: Q1: 0.48 mg/day Q2: 1.04 mg/day Q3: 2.04 mg/day Q4: 5.75 mg/day (FFQ, 1 year prior) Favorable: Significantly decreased CVD risk factors (FBG (95% CI: −1.033 to −0.033); TG (95% CI: −1.998 to −0.029); and heart rate (95% CI: −0.467 to −0.087)). Null: Resveratrol intake was not significantly associated with TC, HDL, LDL and BP [6] Spanish/Spain Cross-sectional study, part of the PREDIMED study N = 7172 (male, 3249; female, 3923) Quintiles: Q1: 0.48 mg/d Q2: 1.04 mg/d Q3: 2.04 mg/day Q4: 5.75 mg/day (FFQ, 1 year prior) Favorable: High dose intake (5.75 mg/d) significantly reduced all-cause mortality by 52% (HR = 0.48; 95% CI: 0.25-0.91) Null: No significant CVD risk reduction (HR = 0.77; 95% CI: 0.35-1.72) [21,22] Swedish/Sweden Case-control study N = 1400 (case, 594 including (OAC, 181; OSCC, 158; JAC, 255)) (control, 806) Control: 0.1 mg/day OAC: 0.07 mg/day OSCC: 0.11 mg/day JAC: 0.09 mg/day (FFQ, 20 years prior) Favorable: In a significantly negative association with the risk of 3 subtypes of esophageal cancer (OAC (95% CI: 0.12-0.49); OSCC (95% CI: 0.15-0.65), and JAC (95% CI: 0.28-0.84)) [5] Italian/Italy Cohort study, "Aging in the Chianti Region" N = 529 (male, 236; female, 293) Tertiles: T1: 0.1 mg/day T2: 0.1-1.1 mg/day T3: >1.1 mg/day (FFQ) Favorable: Inversely associated with the risk of frailty syndrome during the first 3-year follow-up (T3 vs. T1: OR = 0.11; 95% CI: 0.03-0.45) Null: No substantial association with (i) risk of frailty syndrome in 6-, or 9-year follow-up; (ii) inflammatory biomarkers including IL-6, IL-1β, TNF-α, and CRP; (iii) CVD, cancer or all-cause mortality [18] Chinese/Chin...